Novo Nordisk (NVO) May weekly 128 straddle priced into quarter results

Go back to Novo Nordisk (NVO) May weekly 128 straddle priced into quarter results

BofA Securities Comments on Novo Nordisk (NVO)

May 3, 2024 5:55 AM EDT

BofA Securities analyst Sachin Jain reiterated a Buy rating and $147.00 price target on Novo Nordisk (NYSE: NVO)

The analyst comments "Key takes from 1Q results: 1) 1Q24 adjusted EPS DKK5.68 +29%, 8% ahead of consensus, on 2% sales beat and operating margin 300bps ahead, mainly on S&D, offset by lower OOI (-DKK568m vs +DKK33m,... More